Jpmorgan Chase & CO Myovant Sciences Ltd. Transaction History

Jpmorgan Chase & CO

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 13, 2023	SELL	$24.03 - $27.02 $3.22 Million - $3.62 Million	-134,022 Reduced 71.47%	53,492 $1.44 Million
Q3 2022 Nov 14, 2022	SELL	$11.6 - $20.44 $543,773 - $958,165	-46,877 Reduced 20.0%	187,514 $3.37 Million
Q2 2022 Aug 11, 2022	BUY	$7.78 - $14.69 $1.7 Million - $3.21 Million	218,733 Added 1396.94%	234,391 $2.91 Million
Q1 2022 May 11, 2022	BUY	$11.38 - $16.4 $9,445 - $13,611	830 Added 5.6%	15,658 $208,000
Q4 2021 Feb 10, 2022	BUY	$14.31 - $23.87 $19,461 - $32,463	1,360 Added 10.1%	14,828 $230,000
Q3 2021 Nov 12, 2021	BUY	$18.94 - $26.99 $255,083 - $363,501	13,468 New	13,468 $302,000

61.3K

Ticker MYOV
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 96,802,800
Description
Myovant Sciences Ltd., a biopharmaceutical company, develops redefine care for women and for men. The company's lead product is relugolix, an oral, once-daily, small molecule that acts as a gonadotropin-releasing hormone receptor antagonist for the treatment of heavy menstrual bleeding related with uterine fibroids, endometriosis-associated pain...

Get notified when there are updates to the investment portfolio of Jpmorgan Chase & CO, based on Form 13F filings with the SEC.

Stay updated on Jpmorgan Chase & CO with notifications on news.